Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity

Critical Reviews in Oral Biology and Medicine

Volumn 13, Issue 3, 2002, Pages 229-237

  Ganea, Doina ^a   Delgado, Mario ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Macrophages; Neuropeptides; PACAP; T cell apoptosis; T cell cytotoxicity; T cell differentiation; VIP

Indexed keywords

CHEMOKINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOKINE; FAS LIGAND; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; NEUROPEPTIDE; NITRIC OXIDE; PROTEIN C JUN; TRANSCRIPTION FACTOR; VASOACTIVE INTESTINAL POLYPEPTIDE;

CELL DEATH; CYTOTOXICITY; EFFECTOR CELL; HELPER CELL; HUMAN; IMMUNITY; IMMUNOMODULATION; IMMUNOSTIMULATION; INFLAMMATORY CELL; LYMPHOID ORGAN; MACROPHAGE ACTIVATION; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK; TH1 CELL; TH2 CELL;

EID: 0036079049     PISSN: 10454411     EISSN: None     Source Type: Journal    
DOI: 10.1177/154411130201300303     Document Type: Review

References (113)

1. Fas ligand mediates activation-induced cell death in human T lymphocytes
2. Regulation of VIP release from rat enteric nerve terminals: Evidence for a stimulatory effect of NO
3. Neuropeptide innervation of lymphoid organs
4. The CTL kiss of death
5. Dual effects of vasoactive intestinal peptide (VIP) on leucocyte migration
6. Localization of corticotropin-releasing factor in primary and secondary lymphoid organs of the rat
7. Immunohistochemical and immunochemical evidence for expression of human lung PACAP/VIP receptors
8. Uncoupling of inflammatory chemokine receptors by IL-10: Generation of functional decoys
9. Fas-FasL interactions: A common pathogenic mechanism in organ-specific autoimmunity
10. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit IL-12 transcription by regulating NFκB and Ets activation
11. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression
12. VIP and PACAP inhibit antigen induced apoptosis of mature T lymphocytes by inhibiting FasL expression
13. Inhibition of IFNγ-induced Jak1STAT1 activation in macrophages by VIP and PACAP
14. VIP and PACAP inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages
15. Inhibition of endotoxin-induced macrophage chemokine production by VIP and PACAP in vitro and in vivo
16. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NFκB, NF-AT, and early growth factors 2/3
17. Cutting edge: Is vasoactive intestinal peptide a type 2 cytokine?
18. VIP and PACAP inhibit NFκB-dependent gene activation at multiple levels in the human monocytic cell line THP-1
19. VIP and PACAP inhibit Fas ligand-mediated bystander lysis by CD4+ T cells
20. Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes
21. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit TNFα transcriptional activation by regulating NF-kB and CREB/c-Jun
22. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNγ synthesis by T-cells
23. VIP and PACAP38 modulate cytokine and nitric oxide production in peritoneal macrophages and macrophage cell lines
24. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNFα and IL-6
25. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: In vitro and in vivo studies
26. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNFα production by macrophages: In vitro and in vivo studies
27. VIP and PACAP stimulate the induction of Th2 responses by upregulating B7.2 expression
28. VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression
29. VIP and PACAP prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kB and interferon regulatory factor 1 activation
30. Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal receptors: Role in lethal endotoxic shock
31. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease
32. Vasoactive intestinal peptide synergizes with TNF-alpha in inducing human dendritic cell maturation
33. The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes
34. Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cats, and human subjects
35. Cutting edge: Peripheral neuropeptides attract immature and arrest mature blood-derived dendritic cells
36. Nitric oxide: What role does it play in inflammation and tissue destruction?
37. Noradrenergic sympathetic neural interactions with the immune system: Structure and function
38. Noradrenergic and peptidergic innervation of secondary lymphoid organs: Role in experimental rheumatoid arthritis
39. Multiple neuropeptides in nerves supplying mammalian lymph nodes: Messenger candidates for sensory and autonomic neuroimmunomodulation
40. Interleukin-10 inhibits cytokine production by activated macrophages
41. Inhibitory neuropeptide receptors on macrophages
42. Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP
43. Unique pattern of cleavage of VIP by human lymphocytes
44. Selectivity of effects of vasoactive intestinal peptide on macrophages and lymphocytes in compartmental immune responses
45. Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC2 receptor for vasoactive intestinal peptide
46. Immunology of VIP: A review and therapeutical perspectives
47. A new concept in the pharmacology of neuroprotection
48. VIP neuroprotection against excitotoxic lesions of the developing mouse brain
49. Vasoactive intestinal peptide release and L-citrulline production from isolated ganglia of the myenteric plexus: Evidence for regulation of vasoactive intestinal peptide release by nitric oxide
50. Role of cervical lymphotics in the Th2-type hierarchy of CNS immune regulation
51. Nomenclature of receptors for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP)
52. Immunohistochemical localization of peptidergic nerve fibers and neuropeptide receptors in Peyer's patches of the cat ileum
53. VIP1 and VIP2 receptors but not PVR1 mediate the effect of VIP/PACAP on cytokine production in T lymhpocytes
54. Murine T-lymphocytes express vasoactive intestinal peptide receptor 1 (VIP-R1) mRNA
55. Human T lymphocyte chemotaxis and adhesion induced by vasoactive intestinal peptide
56. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation
57. Upregulation of neuropeptides and neuropeptide receptors in a murine model of immune inflammation in lung parenchyma
58. Development of murine allergic asthma is dependent upon B7-2 costimulation
59. B7.1 and B7.2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy
60. Catecholaminergic, cholinergic and peptidergic innervation of gut-associated lymphoid tissue in porcine jejunum and ileum
61. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells
62. Costimulation through CD86 is involved in airway antigen-presenting cell and T cell responses to allergen in atopic asthmatics
63. Macrophages and inflammatory mediators in tissue injury
64. Mature T lymphocyte apoptosis: Immune regulation in a dynamic and unpredictable antigenic environment
65. CD28/B7 system of T cell costimulation
66. Pro-opiomelanocortin messenger ribonucleic acid and posttranslational processing of beta endorphin in spleen macrophages
67. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages
68. IL-4 regulates VIP receptor subtype 2 mRNA (VPAC2) expression in T cells in murine schistosomiasis
69. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells
70. In vivo depression of lymphocyte traffic in sheep by VIP and HIV (AIDS)-related peptides
71. Substance P, calcitonin gene-related peptide, and vasoactive intestinal peptide increase in nasal secretions after allergen challenge in atopic patients
72. IL-13 protects mice from LPS-induced lethal endotoxemia
73. Substance P and beta-endorphin-like immunoreactivity in lavage fluid of subjects with and without allergic asthma
74. The neuroimmune link in the bronchusassociated lymphoid tissue (BALT) of cat and rat: Peptides and neural markers
75. Cytokines induce the development of functionally heterogenous T helper cell subsets
76. Vasoactive intestinal peptide enhancement of antigen-induced differentiation of a cultured line of mouse thymocytes
77. The newer gut hormone. Cellular sources, physiology, pathology, and clinical aspects
78. Immunobiology of vasoactive intestinal peptide (VIP)
79. Gene expression and localization of opioid peptides in immune cells of inflamed tissue: Functional role in antinociception
80. Alpha-MSH production, receptors, and influence on neopterin in a human monocyte/macrophage cell line
81. Pituitary adenylate cyclase activating polypeptide and PACAP/vasoactive intestinal polypeptide receptors: Actions on the anterior pituitary gland
82. Neuroprotective effects of PACAP38 in a rat model of transient focal ischemia under various experimental conditions
83. Somatostatin and substance P-induced in vivo by lipopolysaccharide and in peritoneal macrophages stimulated with lipopolysaccharide or interferon-gamma have differential effects on murine cytokine production
84. A peptide fraction from lung tissue with prolonged peripheral vasodilator activity
85. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses
86. Similar involvement of VIP receptor type I and type II in lymphocyte chemotaxis
87. Neuropeptide Y is an inducible gene in the human immune system
88. Localization of calcitonin gene-related peptide in human esophageal Langerhans cells
89. The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily
90. Fas ligand-mediated bystander lysis of syngeneic cells in response to an allogeneic stimulus
91. Chemokines and dendritic cell traffic
92. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity
93. Neural control of ocular immune privilege
94. Expression of the Fas ligand in cells of the T cell lineage
95. Requirement for splenic CD4+ T cells in the immune privilege of the anterior chamber of the eye
96. The role of the antigen-presenting cell in Fas-mediated direct and bystander killing: Potential in vivo function of Fas in experimental allergic encephalomyelitis
97. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production
98. Deactivation of macrophages by transforming growth factor β
99. Prevention of ischemia-induced death of hippocampal neurons by PACAP
100. Interleukin 6: An overview
101. Differential ability of T cell subsets to undergo activation-induced cell death
102. The pathophysiology of the tumour necrosis factor
103. Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor
104. Expression of atrial natriuretic peptide in thymic macrophages after dexamethasone-treatment of rats
105. CD95-dependent bystander lysis caused by CD4+ T helper 1 effectors
106. Molecular anatomy of the neuro-immune connection
107. Macrophages within the granulomas of murine Schistosoma mansoni are a source of a somatostatin 1-14-like molecule
108. Predominant expression of type II vasoactive intestinal peptide receptors by human T lymphoblastoma cells
109. Vasoactive intestinal peptide inhibits IL-12 and nitric oxide production in murine macrophages
110. Effect of vasoactive intestinal peptide (VIP) on cytokine production and expression of VIP receptors in thymocyte subsets
111. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A
112. Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL mediated apoptosis
113. Chemokines: A new classification system and their role in immunity